About
CLISEQ is a translational diagnostics company spun out of the Weizmann Institute of Science, via its commercialization arm Yeda Research and Development Company Ltd., that is advancing minimally invasive diagnostic approaches for hematologic disorders. The company holds exclusive rights to a patented technology developed at the Weizmann Institute, which enables use of peripheral blood single-cell RNA sequencing (scRNA-seq) to detect conditions such as myelodysplastic syndromes (MDS) as an alternative to bone-marrow aspiration. In partnership with 10x Genomics, Inc. and the Weizmann Institute, CLISEQ is conducting an international multi-site clinical trial (PERIBLOOD) enrolling over 1,500 participants across several continents to validate the technology’s clinical utility and facilitate future diagnostics workflows in hematology.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is CLISEQ's primary focus in diagnostics?
- CLISEQ is a translational diagnostics company focused on advancing minimally invasive diagnostic approaches for hematologic disorders, specifically using peripheral blood single-cell RNA sequencing (scRNA-seq).
- From which institution did CLISEQ spin out?
- CLISEQ spun out of the Weizmann Institute of Science, with its commercialization arm being Yeda Research and Development Company Ltd.
- What patented technology does CLISEQ utilize?
- CLISEQ holds exclusive rights to a patented technology from the Weizmann Institute that uses peripheral blood single-cell RNA sequencing (scRNA-seq) to detect conditions like myelodysplastic syndromes (MDS), offering an alternative to bone-marrow aspiration.
- Is CLISEQ currently involved in any clinical trials?
- Yes, CLISEQ is conducting an international multi-site clinical trial named PERIBLOOD, in partnership with 10x Genomics, Inc. and the Weizmann Institute. This trial aims to enroll over 1,500 participants across several continents to validate their technology's clinical utility.
- When was CLISEQ founded?
- CLISEQ was founded in January 2025.
- What is CLISEQ's current funding stage?
- CLISEQ is currently in the Pre-Seed funding stage, having completed a Pre-Seed round in January 2025.
- Has CLISEQ received any grants?
- Yes, CLISEQ received a grant from the IIA in January 2025.
- What is the approximate employee count for CLISEQ?
- CLISEQ currently has 1-10 employees.
- What was a significant partnership announcement for CLISEQ?
- In September 2025, CLISEQ, 10X Genomics, and the Weizmann Institute announced their collaboration to investigate single-cell applications in hematology clinical diagnostics.